Page 83 - Comprehensive treatment of patients with glucocorticoid-dependent severe asthma

Predictors of benefit from high altitude treatment
Table 3. Associations between patient characteristics at baseline and improvement in the outcomes (Spearman rank correlation).
Patient characteristic
Gender
Age
Asthma onset
Asthma duration
Ever smoking
BMI
Dose of ICS
Dose of OCS
ACQ score
AQLQ score
SNOT-20 score
CIS-fatigue score
FEV1 %pred
6MWD
FeNO
5. Change in
1. Change in OCS
rho p-value
0.19 0.09 0.30 0.01* 0.13 0.25 0.11 0.33
0.02 0.87 -0.17 0.10 -0.16 0.18 -- -- -0.46 <0.01*
0.39 <0.01* -0.23 0.07 -0.10 0.52
-0.21 0.06 0.24 0.05 -0.02 0.84
2. Change in AQLQ
Outcomes
3. Change in 4.Change
FEV1 in Blood BMI
Rho p-value rho p-value
eosinophils
rho p-value
-0.18 0.07 0.06 0.54 0.16 0.13 -0.04 0.66
-0.01 0.93 0.06 0.53 -0.21 0.03*
0.22 0.03* 0.02 0.76 -0.11 0.25 0.10 0.32 0.14 0.16
0.14 0.15 -0.15 0.14 -0.13 0.20 -- --
rho p-value
-0.07 0.38 0.03 0.68 0.04 0.57 0.01 0.85
0.02 0.79 -- -- -0.02 0.80 0.01 0.94 0.07 0.37 -0.12 0.14 0.15 0.07
0.18 0.03*
-0.18 0.03* -0.05 0.62 0.10 0.21 -0.10 0.22
Blood 0.35 <0.01*
eosinophils
Total IgE 0.09 0.43 IgE-HDM 0.07 0.54 Atopy 0.01 0.97
-0.04 0.64 -0.08 0.45 -0.16 0.07 0.06 0.48
0.01 0.97 -0.01 0.98 0.03 0.76 -0.03 0.74
0.31 <0.01* -- --
0.10 0.22 0.22 0.01*
0.01 0.96 -0.01 0.89 -0.13 0.13 -0.07 0.41
-0.04 0.63 -0.02 0.78 0.01 0.89
0.06 0.49 -0.03 0.68 0.05 0.58 -0.05 0.53
0.04 0.59 -0.05 0.58 0.14 0.10 0.06 0.44 0.13 0.14 -0.09 0.29 0.09 0.26 0.01 0.90
-- -- 0.01 0.89 0.04 0.67 0.03 0.71
0.05 0.57 0.01 0.99 -0.03 0.66
0.03 0.74 -0.03 0.68
Footnote table 3: Values from Spearman rank correlation between baseline characteristics and degree of improvement in each outcome. rho for Spearman’s correlation coefficient. *p-value <0.05.
-0.37 <0.01*
-0.25 0.01*
-0.29 <0.01* 0.01 0.90
81
4